Skip to main content
 

Company Overview

480 Biomedical is a clinical stage company developing novel bioresorbable scaffold technologies for the vasculature. 480 Biomedical was founded to advance clinical-stage scaffold technologies from Arsenal Medical.

Learn more about Arsenal Medical at www.arsenalmedical.com

Bioresorbable Scaffold Technology

480 Biomedical's self-expanding scaffold technology platform employs a unique composite design that strikes an optimal balance of strength, flexibility and bioresorption.


Lead Product: Peripheral Artery Disease

Our lead product is the proprietary Stanza™ bioresorbable, drug eluting, scaffold and delivery system for use in treating peripheral artery disease in the superficial femoral artery, a condition that is poorly addressed today.

News

480 Biomedical Announces Funding From Broadview Ventures for Development of Pediatric Scaffold

June 18, 2015

View press release

Arsenal Medical and 480 Biomedical Raise $26.5 Million in Combined Funding for Development of Novel Products to Treat Vascular Disease and Abdominal Trauma

June 1, 2015

View press release

480 Biomedical Awarded $1 Million Phase II NHLBI Contract to Advance Bioresorbable Scaffold for Pediatric Pulmonary Artery Stenosis

July 9, 2014

View press release

BSI Certificate Awarded

December 11, 2013

View press release

Products presented in this website are not available for sale or distribution and are limited to clinical investigational use only.